MILAN–(BUSINESS WIRE)–The biopharmaceutical company Dompé announced the acceptance of the registration application submitted to the European Medicines Agency (EMA) for Oxervate® eye drops, for the treatment of moderate and severe neurotrophic keratitis in adult patients. Acceptance by EMA constitutes the initiation of the dossier’s scientific review procedure, in order to obtain authorisation to market the medicinal product, which was designated an orphan drug for the treatment of neurotrophi
Category: Business
Queratitis neurotrófica: La EMA valida la solicitud de autorización de comercialización para el colirio Cenegermin (Oxervate®) presentado por Dompé
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy la aceptación de la solicitud de inscripción presentada a la Agencia Europea de Medicamentos (European Medicines Agency, EMA) para el colirio Oxervate®, para el tratamiento de queratitis neurotrófica de moderada a grave en pacientes adultos. La aceptación por parte de la EMA supone el inicio del procedimiento de revisión científica del expediente con el fin de conseguir la autorización para la comercialización del medicam
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced that the primary endpoint was not achieved in its two pivotal Phase 3 clinical trials investigating Fovista® (pegpleranib).
North America $100 Billion Vision Care Market: Industry Analysis and Opportunity Assessment, 2016-2026 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Vision Care Market: North America Industry Analysis and Opportunity Assessment, 2016-2026” report to their offering. North America vision care market is projected to regis…
SageGlass Announces Completion of Dynamic Glass Installation at Bellavista Eye Clinic in Switzerland
MINNEAPOLIS–(BUSINESS WIRE)–SageGlass®, the pioneer of the world’s smartest electrochromic glass, installed dynamic glass on the floor-to-ceiling façade of the new 263,715-square-foot Bellavista Eye Clinic in Speicher, Switzerland. SageGlass, a product of Saint-Gobain, was chosen for its ability to provide access to natural daylight, which has been proven to be a major contributing factor to the patient recovery process. Extensive research has shown how light affects a patient’s wellbeing and
Listing of Kubota Pharmaceutical Holdings Co., Ltd. and Forecast for Fiscal Year End 2016
TOKYO–(BUSINESS WIRE)–Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (the “Company”) hereby gives notice that the merger agreement regarding its proposed redomicile transaction became effective on December 1, 2016 Japan Time. On December 6, 2016 Japan Time, the Company has been listed on the Mothers market of the Tokyo Stock Exchange, Inc. (“TSE”). The Company has also announced earnings and dividend forecasts for the fiscal year end 2016 as follows. 1. Overview of Kubota Pharmaceutic
The American Refractive Surgery Council is Available to Comment on JAMA Ophthalmology Study
DALLAS–(BUSINESS WIRE)–For the first time, a statistically-valid questionnaire is available to surgeons and researchers for LASIK patients to report and surgeons to scientifically track their experiences with LASIK.
Glaucoma Pipeline Highlights Report – H2 2016 Update – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Glaucoma Pipeline Highlights – 2016 Update” drug pipelines to their offering. Glaucoma Pipeline Highlights – 2016 Update, provides most up-to-date information on key pipel…
Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% in pediatric patients undergoing cataract surgery. OMIDRIA is approved by the FDA for use in adult patients undergoing cataract or intraocular lens replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postop
Global LASIK Treatment Market Research Report 2015-2022 – Analysis, Technologies & Forecasts – Vendors: Abbott Medical Optics, Carl Zeiss, Nidek – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global LASIK Treatment Market Research Report – Industry Analysis, Size, Share, Growth, Trends And Forecast” report to their offering. The report on global LASIK (laser-as…
Glaukos Announces Participation in Piper Jaffray Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ADVANCE, a Phas…
America’s Best Contacts & Eyeglasses Named Official National Partner of Monster Jam®
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Inc., one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, and Feld Entertainment, the worldwide leader in producing live family entertainment, announced today National Vision’s America’s Best Contacts & Eyeglasses brand as an official partner of Monster Jam®. The collaboration includes cross-promotion, advertising and fully immersive experiences for both America’s Best customers and Monster Jam fans.
Ocular Therapeutix™ Announces Successful Topline Results for Both Inflammation and Pain Primary Efficacy Endpoints from Phase 3 Clinical Trial of DEXTENZA™
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert
Neue bahnbrechende Studie belegt Vermeidbarkeit von Sehverlust bei Erwachsenen mit Diabetes
NEWBURY, England–(BUSINESS WIRE)–Obwohl die Angst vor Sehverlust doppelt so hoch ist wie die Angst vor anderen häufigen mit Diabetes verbundenen Komplikationen (einschließlich Herzkreislauferkrankungen und Schlaganfall), bespricht ein Viertel der befragten Patienten mit Diabetes das Thema Augenkomplikationen nicht mit medizinischem Fachpersonal, während viele erst ärztlichen Rat suchen, wenn Sehkraftprobleme bereits vorhanden sind.1 Dies sind einige der besorgniserregenden Erkenntnisse aus de
New landmark study reveals adults with diabetes at unnecessary risk of vision loss
NEWBURY, England–(BUSINESS WIRE)–Despite vision loss being feared twice as much as other common complications of diabetes (including cardiovascular disease and stroke) a quarter of people with diabetes surveyed are not discussing eye complications wi…
EyeQue Awarded CES 2017 Best of Innovation
NEW YORK & NEWARK, Calif.–(BUSINESS WIRE)–The EyeQue Personal Vision Tracker earned the highest honor for CES 2017- Best of Innovation in the Fitness, Sports and Biotech category.
Glaukos Corporation Announces Third Quarter 2016 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Tobii Pro Launches Pioneering Eye Tracker and Biometric Software Platform for Behavioral Research
STOCKHOLM–(BUSINESS WIRE)–Tobii Pro (STO:TOBII), the global leader in eye tracking research solutions, continues to push the envelope in eye tracking innovation with the launch of Tobii Pro Spectrum and Tobii Pro Lab, its most advanced eye tracking solutions to date. These research tools – to be exhibited at Neuroscience 2016 (https://www.sfn.org/annual-meeting/neuroscience-2016) in San Diego, Calif. – from November 12-16 – will further expand the scope and richness of what can be achieved in
Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016